CT-P52 (ixekizumab biosimilar) / Celltrion - LARVOL DELTA

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects (clinicaltrials.gov) - P1 | N=218 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed